Description
Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.
Key applications of liquid biopsy testing in clinical oncology include:
- Early Detection and Diagnosis/Screening:
- Identifying cancer at an early stage.
- Alternative Testing Method:
- When tissue biopsy is challenging or impossible.
- When the primary site of metastatic disease is unknown.
- Therapy Personalization and Monitoring:
- Molecular characterization to select optimal therapy.
- Monitoring treatment efficacy and adjusting therapy in case of resistance.
- Disease Monitoring:
- Observing disease progression, tumor evolution, residual disease.
- Early detection of recurrence.
- Prognosis of Disease:
- Assessing the likely course and outcome of the disease.
The liquid biopsy market is experiencing significant changes, and The Worldwide Market for Liquid Biopsy, 6th Edition from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. The brand new market research report covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.
Key Market Segments:
- By Region:
- North America
- Europe
- Asia
- Rest of World
- By Type of Liquid Biopsy:
- CTC-based Liquid Biopsy
- ctDNA-based Liquid Biopsy
- EV and Exosome-based Liquid Biopsy
- Multi-Analyte-based Liquid Biopsy
- Other Analytes Liquid Biopsy
- By Type of Cancer:
- Breast
- Lung
- Colorectal
- Ovarian
- Prostate
- Pan-Cancer
- Other Cancers
- R&D and Selected Tests:
- Selected ctDNA-based Liquid Biopsy Tests in Development
- Selected CTC-based Liquid Biopsy Tests in 2023
- Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023
The growing acceptance of liquid biopsy, even during the COVID-19 pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy’s potential in combination with other technologies further contributes to its expanding applications and market growth.
The report also profiles key companies in the liquid biopsy market. These include:
Top of Form
Bottom of Form
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- Angle, PLC
- Aspira Women’s Health
- Biocartis Group Nv
- Biocept, Inc. (closed)
- Biodesix
- Cellmax Life
- Circulogene
- Diacarta, Inc.
- Epic Sciences
- Epigenomics AG (closed)
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- Gilupi Gmbh
- Grail (Illumina)
- Guardant Health, Inc.
- Hologic
- Lunglife AI (Formerly Cynvenio Biosystems)
- Menarini-Silicon Biosystems, SPA
- Myriad Genetics, Inc.
- Natera, Inc.
- Neogenomics Laboratories, Inc.
- Oncocyte Corporation
- Oncodna S.A.
- Personal Genome Diagnostics
- Qiagen N.V.
- Cell-Free DNA Technologies
- Ctc Technologies
- Exosome And Mirna Technologies
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- Volitionrx
Table of Contents
Chapter One: Executive Summary
Introduction
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast
- Figure 1-1: Market for Liquid Biopsy, 2023-2028 ($M)
- Figure 1-2: Global Liquid Biopsy Market Share, by Geographic Region, 2023 (%)
- Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2023-2028 ($M)
Chapter Two: Liquid Biopsy Technologies
Introduction
- Table 2-1: Comparison of Tissue and Liquid Biopsy
Current Major Liquid Biopsy Technologies
- Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
Introduction
Advantages and Limitations of ctDNA in Liquid Biopsy
Current ctDNA-based Liquid Biopsy Tests
- Table 3-1: Selected ctDNA-based Liquid Biopsy Tests, 2023
Biocartis
Biodesix
CellMax Life
Circulogene
Diacarta
Foundation Medicine (Roche)
Guardant Health
Inivata (Neogenomics)
LungLife AI
Myriad Genetics
NeoGenomics
OncoDNA
Personal Genomic Diagnostics (LabCorp)
QIAGEN
Resolution Biosciences (Exact Sciences)
Roche Diagnostics
Sysmex-Inostics
Tempus
ctDNA-based Liquid Biopsy Tests in Development
Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2023
Freenome
GRAIL
Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
Introduction
Challenges in the Development of CTC-based Liquid Biopsy Tests
CTC-based Liquid Biopsy Tests
- Table 4-1: Selected CTC-based Liquid Biopsy Tests, 2023
Adaptive Biotechnologies
ANGLE
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN
Selected CTC-based Liquid Biopsy Tests in Development
- Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2023
Epic Sciences
Liquid Biotech USA
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
Introduction
Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
- Table 5-1: Selected Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2023
Aspira Women’s Health (formerly Vermillion)
Biodesix
Exosome Diagnostics
Hologic
MDxHealth
Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
- Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2023
Circulogene
OncoCyte
Resolution Biosciences (Exact Sciences)
VolitionRx
Chapter Six: Multi-Analyte Liquid Biopsy Tests
Introduction
Liquid Biopsy Tests Based on Multiple Analytes
- Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2023
Biodesix
Foundation Medicine (Roche)
LungLife AI
NeoGenomics
OncoDNA
Multiple Analyte-based Liquid Biopsy Tests in Development
- Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2023
Exact Sciences
Freenome
GRAIL
LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
Introduction
Liquid Biopsy Tests for Research Use Only
- Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2023
Agena Bioscience
DiaCarta
Exosome Diagnostics
Guardant Health
Natera
QIAGEN
Chapter Eight: Liquid Biopsy Industry Analysis
Introduction
Tiers of Competition
- Table 8-1: Selected Participants in the Liquid Biopsy Market, 2023
Competitive Factors
Significant Market Trends
- Table 8-2: Significant Trends in the Liquid Biopsy Market, 2023
Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
Competitors No Longer in the Liquid Biopsy Market
- Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
Market Overview
- Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate, by Region, 2023-2028 ($M)
- Figure 1-2: Global Liquid Biopsy Market, by Geographic Region, 2023 ($M)
- Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimated Share, by Region, 2023 (%)
Market Forecast
- Figure 9-3: Global Liquid Biopsy Market Forecast, by Region (North America, Europe, Asia Pacific, Rest of World), 2023-2028 ($M)
Chapter Ten: Market by Analyte
Circulating Tumor DNA
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-1: Global Liquid Biopsy Market for ctDNA, 2023-2028 ($M)
Circulating Tumor Cells
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-2: Global Liquid Biopsy Market for CTCs, 2023-2028 ($M)
Extracellular Vesicles and Other Analytes
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
- Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles, 2023-2028 ($M)
Multiple Analytes
Market Overview
Revenue Forecast
- Table 10-4: Global Liquid Biopsy Market for Multiple Analytes, 2023-2028 ($M)
Chapter Eleven: Market by Application
Therapy Guidance and Monitoring
Market Overview
Revenue Forecast
- Table 11-1: Liquid Therapy for Therapy Guidance, 2023-2028 ($M)
Diagnosis/Screening
Market Overview
Revenue Forecast
- Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening, 2023-2028 ($M)
Disease Prognosis
Market Overview
Revenue Forecast
- Table 11-3: Global Liquid Biopsy Market for Disease Prognosis, 2023-2028 ($M)
Chapter Twelve: Market by Cancer Type
Breast Cancer
Market Overview
Revenue Forecast
- Table 12-1: Global Liquid Biopsy Market for Breast Cancer, 2023-2028 ($M)
Colorectal Cancer
Market Overview
Revenue Forecast
- Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer, 2023-2028 ($M)
Lung Cancer
Market Overview
Revenue Forecast
- Table 12-3: Global Liquid Biopsy Market for Lung Cancer, 2023-2028 ($M)
Ovarian Cancer
Market Overview
Revenue Forecast
- Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer, 2023-2028 ($M)
Prostate Cancer
Market Overview
Revenue Forecast
- Table 12-5: Global Liquid Biopsy Market for Prostate Cancer, 2023-2028 ($M)
Other Cancers
Market Overview
Revenue Forecast
- Table 12-6: Global Liquid Biopsy Market for Other Cancers, 2023-2028 ($M)
Pan-Cancer Tests
Market Overview
Revenue Forecast
- Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing, 2023-2028 ($M)
Chapter Thirteen: Company Profiles
Companies in the Market
- Table 13-1 Companies in the Liquid Biopsy Market
Adaptive Biotechnologies
Company Overview
Agena Bioscience, Inc.
Company Overview
ANGLE, plc
Company Overview
Aspira Women’s Health
Company Overview
Biocartis Group NV
Company Overview
Biocept, Inc. (closed)
Company Overview
Biodesix
Company Overview
CellMax Life
Company Overview
Circulogene
Company Overview
DiaCarta, Inc.
Company Overview
Epic Sciences
Company Overview
Epigenomics AG (closed)
Company Overview
Exact Sciences
Company Overview
Exosome Diagnostics, Inc.
Company Overview
Foundation Medicine, Inc. (Roche)
Company Overview
Freenome, Inc.
Company Overview
GILUPI GmbH
Company Overview
GRAIL (Illumina)
Company Overview
Guardant Health, Inc.
Company Overview
Hologic
Company Overview
LungLife AI (formerly Cynvenio Biosystems)
Company Overview
Company Overview
Menarini-Silicon Biosystems, Spa
Company Overview
Myriad Genetics, Inc.
Company Overview
Natera, Inc.
Company Overview
NeoGenomics Laboratories, Inc.
Company Overview
Oncocyte Corporation
Company Overview
OncoDNA S.A.
Company Overview
Personal Genome Diagnostics
Company Overview
QIAGEN N.V.
Company Overview
Cell-free DNA Technologies
CTC Technologies
Exosome and miRNA Technologies
Resolution Biosciences (Agilent)
Company Overview
Roche Diagnostics
Company Overview
Sysmex-Inostics, Inc.
Company Overview
Tempus
Company Overview
VolitionRx
Company Overview
